{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T06:14:03Z","timestamp":1758608043038,"version":"3.44.0"},"reference-count":111,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.clml.2025.04.016","type":"journal-article","created":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T05:18:38Z","timestamp":1745558318000},"page":"689-697","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["SOHO State of the Art Updates and Next Questions | Transplant in Adult Acute Lymphoblastic Leukemia"],"prefix":"10.1016","volume":"25","author":[{"given":"Curtis","family":"Marcoux","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8607-9404","authenticated-orcid":false,"given":"Partow","family":"Kebriaei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.clml.2025.04.016_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2024.100466","volume":"37","author":"Choi","year":"2024","journal-title":"Mod Pathol"},{"issue":"5","key":"10.1016\/j.clml.2025.04.016_bib0002","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1182\/blood-2016-07-726588","article-title":"Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults","volume":"129","author":"Jain","year":"2017","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2025.04.016_bib0003","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1200\/JCO.2016.69.0073","article-title":"High frequency and poor outcome of Philadelphia chromosome-like acute lymphoblastic leukemia in adults","volume":"35","author":"Roberts","year":"2017","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.clml.2025.04.016_bib0004","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.clml.2025.04.016_bib0005","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2025.04.016_bib0006","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.clml.2025.04.016_bib0007","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.3324\/haematol.2020.247973","article-title":"Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913","volume":"106","author":"Chiaretti","year":"2021","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.clml.2025.04.016_bib0008","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1038\/s41409-021-01262-5","article-title":"Outcomes in patients with CRLF2 overexpressed acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation","volume":"56","author":"Koller","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"17","key":"10.1016\/j.clml.2025.04.016_bib0009","doi-asserted-by":"crossref","first-page":"4936","DOI":"10.1182\/bloodadvances.2022007597","article-title":"Outcomes of allogeneic hematopoietic cell transplantation in adults with fusions associated with Ph-like ALL","volume":"6","author":"Aldoss","year":"2022","journal-title":"Blood Adv"},{"issue":"8","key":"10.1016\/j.clml.2025.04.016_bib0010","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1038\/s41409-021-01253-6","article-title":"Non-inferior long-term outcomes of adults with Philadelphia chromosome-like acute lymphoblastic leukemia","volume":"56","author":"Cho","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.04.016_bib0011","doi-asserted-by":"crossref","first-page":"656-","DOI":"10.1182\/blood-2023-178150","article-title":"A multicenter analysis of allogeneic transplant outcomes in patients with Philadelphia-like (Ph-like) acute lymphoblastic leukemia (ALL)","volume":"142","author":"Abdel Rahman","year":"2023","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.clml.2025.04.016_bib0012","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2018-10-881961","article-title":"A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403","volume":"133","author":"Stock","year":"2019","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2025.04.016_bib0013","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1056\/NEJMoa0808253","article-title":"Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia","volume":"360","author":"Mullighan","year":"2009","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.clml.2025.04.016_bib0014","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/s41375-023-01877-1","article-title":"The KMT2A recombinome of acute leukemias in 2023","volume":"37","author":"Meyer","year":"2023","journal-title":"Leukemia"},{"issue":"23","key":"10.1016\/j.clml.2025.04.016_bib0015","doi-asserted-by":"crossref","first-page":"5415","DOI":"10.1182\/bloodadvances.2021004580","article-title":"Outcomes of acute lymphoblastic leukemia with KMT2A (MLL) rearrangement: the MD Anderson experience","volume":"5","author":"Richard-Carpentier","year":"2021","journal-title":"Blood Adv"},{"issue":"16","key":"10.1016\/j.clml.2025.04.016_bib0016","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1182\/blood-2017-05-783852","article-title":"Impact of cytogenetic abnormalities in adults with ph-negative B-cell precursor acute lymphoblastic leukemia","volume":"130","author":"Lafage-Pochitaloff","year":"2017","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.clml.2025.04.016_bib0017","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1182\/blood.2023021501","article-title":"Genetic alterations and MRD refine risk assessment for KMT2A-rearranged B-cell precursor ALL in adults: a GRAALL study","volume":"142","author":"Kim","year":"2023","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2025.04.016_bib0018","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1038\/s41375-024-02209-7","article-title":"Measurable residual disease quantification in adult patients with KMT2A-rearranged acute lymphoblastic leukemia","volume":"38","author":"Burmeister","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2025.04.016_bib0019","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1182\/blood-2023-172422","article-title":"A first-in-Human phase 1 study of the Menin-KMT2A (MLL1) inhibitor JNJ-75276617 in adult patients with relapsed\/refractory acute leukemia harboring KMT2A or NPM1 alterations","volume":"142","author":"Jabbour","year":"2023","journal-title":"Blood"},{"issue":"Supplement 2","key":"10.1016\/j.clml.2025.04.016_bib0020","doi-asserted-by":"crossref","first-page":"LBA","DOI":"10.1182\/blood-2023-192042","article-title":"Revumenib monotherapy in patients with relapsed\/refractory KMT2Ar acute leukemia: topline efficacy and safety results from the pivotal augment-101 phase 2 study","volume":"142","author":"Aldoss","year":"2023","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.clml.2025.04.016_bib0021","doi-asserted-by":"crossref","first-page":"4489","DOI":"10.1182\/blood-2009-01-199380","volume":"113","author":"Fielding","year":"2009","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2025.04.016_bib0022","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1182\/blood-2002-03-0704","article-title":"Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia\u2013results of the prospective multicenter LALA-94 trial","volume":"100","author":"Dombret","year":"2002","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2025.04.016_bib0023","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1182\/blood-2015-03-636548","article-title":"Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia","volume":"126","author":"Kim","year":"2015","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2025.04.016_bib0024","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1182\/bloodadvances.2016001495","article-title":"US intergroup study of chemotherapy plus Dasatinib and allogeneic stem cell transplant in Philadelphia chromosome positive ALL","volume":"1","author":"Ravandi","year":"2016","journal-title":"Blood Adv"},{"issue":"22","key":"10.1016\/j.clml.2025.04.016_bib0025","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1182\/bloodadvances.2021004813","article-title":"Dasatinib and dexamethasone followed by hematopoietic cell transplantation for adults with ph-positive ALL","volume":"5","author":"Wieduwilt","year":"2021","journal-title":"Blood Adv"},{"issue":"24","key":"10.1016\/j.clml.2025.04.016_bib0026","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1182\/blood-2015-02-627935","article-title":"Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with ph-positive acute lymphoblastic leukemia","volume":"125","author":"Chalandon","year":"2015","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.clml.2025.04.016_bib0027","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1182\/blood-2015-02-627935","article-title":"Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with ph-positive acute lymphoblastic leukemia","volume":"125","author":"Chalandon","year":"2015","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.clml.2025.04.016_bib0028","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1182\/blood.2022016194","article-title":"The role of allogeneic transplant for adult ph+ ALL in CR1 with complete molecular remission: a retrospective analysis","volume":"140","author":"Ghobadi","year":"2022","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2025.04.016_bib0029","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/ajh.26816","article-title":"Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up results","volume":"98","author":"Kantarjian","year":"2023","journal-title":"Am J Hematol"},{"issue":"17","key":"10.1016\/j.clml.2025.04.016_bib0030","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa2016272","article-title":"Dasatinib-Blinatumomab for ph-positive acute lymphoblastic leukemia in adults","volume":"383","author":"Fo\u00e0","year":"2020","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.clml.2025.04.016_bib0031","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1200\/JCO.23.01075","article-title":"Long-term results of the Dasatinib-Blinatumomab protocol for adult Philadelphia-positive ALL","volume":"42","author":"Fo\u00e0","year":"2024","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.clml.2025.04.016_bib0032","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1001\/jama.2024.4783","article-title":"Ponatinib vs Imatinib in frontline Philadelphia chromosome-positive acute lymphoblastic leukemia: a randomized clinical trial","volume":"331","author":"Jabbour","year":"2024","journal-title":"Jama"},{"issue":"1","key":"10.1016\/j.clml.2025.04.016_bib0033","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1016\/S2352-3026(22)00319-2","article-title":"Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial","volume":"10","author":"Jabbour","year":"2023","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2025.04.016_bib0034","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1182\/blood-2024-206602","article-title":"Blinatumomab and Ponatinib for adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: updated results and predictors of relapse","volume":"144","author":"Short","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2025.04.016_bib0035","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3324\/haematol.2017.176917","volume":"103","author":"Cazzaniga","year":"2018","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.clml.2025.04.016_bib0036","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1002\/ajh.26949","article-title":"Ultrasensitive NGS MRD assessment in Ph+\u2009ALL: prognostic impact and correlation with RT-PCR for BCR::ABL1","volume":"98","author":"Short","year":"2023","journal-title":"Am J Hematol"},{"issue":"13","key":"10.1016\/j.clml.2025.04.016_bib0037","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1182\/bloodadvances.2022007378","article-title":"High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse","volume":"6","author":"Short","year":"2022","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.clml.2025.04.016_bib0038","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S1470-2045(08)70314-0","article-title":"Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia","volume":"10","author":"Coustan-Smith","year":"2009","journal-title":"Lancet Oncol"},{"issue":"15","key":"10.1016\/j.clml.2025.04.016_bib0039","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1182\/blood-2015-08-661702","article-title":"Early T-cell precursor acute lymphoblastic leukemia\/lymphoma (ETP-ALL\/LBL) in adolescents and adults: a high-risk subtype","volume":"127","author":"Jain","year":"2016","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2025.04.016_bib0040","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/s41375-019-0598-2","article-title":"T-cell acute lymphoblastic leukemia in patients 1-45 years treated with the pediatric NOPHO ALL2008 protocol","volume":"34","author":"Quist-Paulsen","year":"2020","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.clml.2025.04.016_bib0041","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/j.1365-2141.2011.08955.x","article-title":"Clinical significance of early T-cell precursor acute lymphoblastic leukaemia: results of the Tokyo Children's Cancer Study Group Study L99-15","volume":"156","author":"Inukai","year":"2012","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.clml.2025.04.016_bib0042","doi-asserted-by":"crossref","first-page":"e80","DOI":"10.1016\/S2352-3026(15)00254-9","article-title":"Early T-cell precursor acute lymphoblastic leukaemia in children treated in AIEOP centres with AIEOP-BFM protocols: a retrospective analysis","volume":"3","author":"Conter","year":"2016","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1016\/j.clml.2025.04.016_bib0043","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28719","article-title":"Identification of prognostic factors in childhood T-cell acute lymphoblastic leukemia: results from DFCI ALL Consortium protocols 05-001 and 11-001","volume":"68","author":"Burns","year":"2021","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"10.1016\/j.clml.2025.04.016_bib0044","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/bjh.12882","article-title":"Outcome for children and young people with early T-cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003","volume":"166","author":"Patrick","year":"2014","journal-title":"Br J Haematol"},{"issue":"23","key":"10.1016\/j.clml.2025.04.016_bib0045","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1200\/JCO.2016.71.8585","article-title":"Early response-based therapy stratification improves survival in adult Early thymic precursor acute lymphoblastic leukemia: a group for research on adult acute lymphoblastic leukemia study","volume":"35","author":"Bond","year":"2017","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clml.2025.04.016_bib0046","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/bmt.2016.194","article-title":"Multi-center analysis of the effect of T-cell acute lymphoblastic leukemia subtype and minimal residual disease on allogeneic stem cell transplantation outcomes","volume":"52","author":"Brammer","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"10.1016\/j.clml.2025.04.016_bib0047","doi-asserted-by":"crossref","first-page":"5477","DOI":"10.1182\/blood-2008-01-132837","article-title":"Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study","volume":"111","author":"Borowitz","year":"2008","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.clml.2025.04.016_bib0048","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.3324\/haematol.2018.201053","article-title":"A systematic literature review and meta-analysis of minimal residual disease as a prognostic indicator in adult B-cell acute lymphoblastic leukemia","volume":"104","author":"Bassan","year":"2019","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.clml.2025.04.016_bib0049","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.0580","article-title":"Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis","volume":"3","author":"Berry","year":"2017","journal-title":"JAMA Oncol"},{"issue":"15","key":"10.1016\/j.clml.2025.04.016_bib0050","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1200\/JCO.2013.52.2425","volume":"32","author":"Ribera","year":"2014","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.clml.2025.04.016_bib0051","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/s41409-018-0373-4","volume":"54","author":"Giebel","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"10.1016\/j.clml.2025.04.016_bib0052","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1182\/blood-2011-09-377713","article-title":"Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies","volume":"120","author":"G\u00f6kbuget","year":"2012","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.clml.2025.04.016_bib0053","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1182\/blood-2014-09-599894","article-title":"Role of allogeneic stem cell transplantation in adult patients with ph-negative acute lymphoblastic leukemia","volume":"125","author":"Dh\u00e9din","year":"2015","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2025.04.016_bib0054","doi-asserted-by":"crossref","first-page":"e225","DOI":"10.1038\/bcj.2014.48","article-title":"Different molecular levels of post-induction minimal residual disease may predict hematopoietic stem cell transplantation outcome in adult Philadelphia-negative acute lymphoblastic leukemia","volume":"4","author":"Bassan","year":"2014","journal-title":"Blood Cancer J"},{"issue":"5","key":"10.1016\/j.clml.2025.04.016_bib0055","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/ajh.25417","article-title":"Minimal residual disease status determined by multiparametric flow cytometry pretransplantation predicts the outcome of patients with ALL receiving unmanipulated haploidentical allografts","volume":"94","author":"Zhao","year":"2019","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.clml.2025.04.016_bib0056","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s13045-019-0790-x","article-title":"Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT","volume":"12","author":"Pavl\u016f","year":"2019","journal-title":"J Hematol Oncol"},{"issue":"2","key":"10.1016\/j.clml.2025.04.016_bib0057","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1182\/bloodadvances.2020003536","article-title":"Measurable residual disease affects allogeneic hematopoietic cell transplantation in ph+ ALL during both CR1 and CR2","volume":"5","author":"Nishiwaki","year":"2021","journal-title":"Blood Adv"},{"issue":"12","key":"10.1016\/j.clml.2025.04.016_bib0058","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.jtct.2022.08.024","article-title":"Long-term results of allogeneic stem cell transplantation in adult ph- negative high-risk acute lymphoblastic leukemia","volume":"28","author":"Beelen","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"9","key":"10.1016\/j.clml.2025.04.016_bib0059","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.clml.2024.02.017","article-title":"SOHO State of the art updates and next questions | novel agents and the diminishing role of allogeneic stem cell transplant in B-acute lymphoblastic leukemia","volume":"24","author":"Jen","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"10.1016\/j.clml.2025.04.016_bib0060","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1182\/bloodadvances.2024015441","article-title":"Clinical use of measurable residual disease in adult ALL: recommendations from a panel of U.S. experts","volume":"9","author":"Short","year":"2025","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.clml.2025.04.016_bib0061","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s13045-022-01379-0","article-title":"Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study","volume":"15","author":"Shah","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"5","key":"10.1016\/j.clml.2025.04.016_bib0062","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.clml.2025.04.016_bib0063","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2406526","article-title":"Obecabtagene autoleucel in adults with B-cell acute lymphoblastic leukemia","volume":"391","author":"Roddie","year":"2024","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.clml.2025.04.016_bib0064","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1182\/blood-2018-11-883710","article-title":"Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy","volume":"133","author":"Hay","year":"2019","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2025.04.016_bib0065","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.22.00642","article-title":"Three-year update of Tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia in the ELIANA trial","volume":"41","author":"Laetsch","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.04.016_bib0066","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1182\/blood-2023-182531","article-title":"Brexucabtagene Autoleucel in adults with relapsed\/refractory B-cell ALL: outcomes and novel insights from the real-world Outcomes collaborative of CAR T in adult ALL (ROCCA)","volume":"142","author":"Roloff","year":"2023","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2025.04.016_bib0067","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1158\/1078-0432.CCR-22-2038","article-title":"Favorable activity and safety profile of memory-enriched CD19-targeted chimeric antigen receptor T-cell therapy in adults with high-risk relapsed\/refractory ALL","volume":"29","author":"Aldoss","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"15","key":"10.1016\/j.clml.2025.04.016_bib0068","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1200\/JCO.20.02262","article-title":"Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL","volume":"39","author":"Shah","year":"2021","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.clml.2025.04.016_bib0069","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1002\/ajh.25582","article-title":"Anti-CD19 chimeric antigen receptor-modified T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed\/refractory B-cell acute lymphoblastic leukemia: an open-label pragmatic clinical trial","volume":"94","author":"Jiang","year":"2019","journal-title":"Am J Hematol"},{"issue":"20","key":"10.1016\/j.clml.2025.04.016_bib0070","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1182\/bloodadvances.2019000593","article-title":"Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy","volume":"3","author":"Shadman","year":"2019","journal-title":"Blood Adv"},{"issue":"10","key":"10.1016\/j.clml.2025.04.016_bib0071","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1182\/bloodadvances.2020001466","article-title":"Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features","volume":"4","author":"Zhang","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.clml.2025.04.016_bib0072","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jtct.2021.10.003","article-title":"Hematopoietic cell transplantation after CD19 chimeric antigen receptor T cell-induced acute lymphoblastic lymphoma remission confers a leukemia-free survival advantage","volume":"28","author":"Summers","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"11","key":"10.1016\/j.clml.2025.04.016_bib0073","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1038\/s41409-020-0926-1","article-title":"Low toxicity and favorable overall survival in relapsed\/refractory B-ALL following CAR T cells and CD34-selected T-cell depleted allogeneic hematopoietic cell transplant","volume":"55","author":"Fabrizio","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"10.1016\/j.clml.2025.04.016_bib0074","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.jtct.2024.06.013","article-title":"Consolidation with first and second allogeneic transplants in adults with relapsed\/refractory B-ALL following response to CD19CAR T cell therapy","volume":"30","author":"Aldoss","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"9","key":"10.1016\/j.clml.2025.04.016_bib0075","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1200\/JCO.20.03585","article-title":"Disease burden affects outcomes in pediatric and young adult B-cell lymphoblastic leukemia after commercial tisagenlecleucel: a pediatric real-world chimeric antigen receptor Consortium report","volume":"40","author":"Schultz","year":"2022","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.clml.2025.04.016_bib0076","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1200\/JCO.21.01405","article-title":"Blinatumomab nonresponse and high-disease burden are associated with inferior outcomes after CD19-CAR for B-ALL","volume":"40","author":"Myers","year":"2022","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.clml.2025.04.016_bib0077","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1182\/bloodadvances.2019000692","article-title":"CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy","volume":"3","author":"Pillai","year":"2019","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.clml.2025.04.016_bib0078","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1158\/2643-3230.BCD-21-0095","article-title":"Next-generation sequencing of minimal residual disease for predicting relapse after tisagenlecleucel in children and young adults with acute lymphoblastic leukemia","volume":"3","author":"Pulsipher","year":"2022","journal-title":"Blood Cancer Discov"},{"issue":"12","key":"10.1016\/j.clml.2025.04.016_bib0079","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1038\/s41375-021-01281-7","article-title":"Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia","volume":"35","author":"Dourthe","year":"2021","journal-title":"Leukemia"},{"issue":"10299","key":"10.1016\/j.clml.2025.04.016_bib0080","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.clml.2025.04.016_bib0081","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1200\/JCO.20.02529","article-title":"Total body irradiation or chemotherapy conditioning in childhood ALL: a multinational, randomized, noninferiority phase III study","volume":"39","author":"Peters","year":"2021","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clml.2025.04.016_bib0082","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1200\/JCO.22.00767","article-title":"Busulfan plus cyclophosphamide versus total body irradiation plus cyclophosphamide for adults acute B lymphoblastic leukemia: an open-label, multicenter, phase III trial","volume":"41","author":"Zhang","year":"2023","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.clml.2025.04.016_bib0083","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1016\/j.bbmt.2019.08.012","article-title":"Comparison of high doses of total body irradiation in myeloablative conditioning before hematopoietic cell transplantation","volume":"25","author":"Sabloff","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1016\/j.clml.2025.04.016_bib0084","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1200\/JCO.2000.18.5.981","article-title":"Prospective randomized comparison of single-dose versus hyperfractionated total-body irradiation in patients with hematologic malignancies","volume":"18","author":"Girinsky","year":"2000","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clml.2025.04.016_bib0085","doi-asserted-by":"crossref","first-page":"e812","DOI":"10.1097\/HS9.0000000000000812","article-title":"Reduced 8-gray compared to standard 12-gray total body irradiation for allogeneic transplantation in first remission acute lymphoblastic leukemia: a study of the acute leukemia Working party of the EBMT","volume":"7","author":"Spyridonidis","year":"2023","journal-title":"Hemasphere"},{"issue":"10","key":"10.1016\/j.clml.2025.04.016_bib0086","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/ajh.24823","volume":"92","author":"Eder","year":"2017","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.clml.2025.04.016_bib0087","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.bbmt.2017.11.025","article-title":"Intravenous busulfan compared with total body irradiation pretransplant conditioning for adults with acute lymphoblastic leukemia","volume":"24","author":"Kebriaei","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"10.1016\/j.clml.2025.04.016_bib0088","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.jtct.2021.03.026","article-title":"Impact of total body irradiation-based myeloablative conditioning regimens in patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation: systematic review and meta-analysis","volume":"27","author":"Khimani","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"10.1016\/j.clml.2025.04.016_bib0089","doi-asserted-by":"crossref","first-page":"e232","DOI":"10.1016\/j.clml.2024.12.007","article-title":"Efficacy and safety of total body irradiation versus chemotherapy conditioning for hematopoietic stem cell transplant in adult acute lymphoblastic leukemia: a systematic review and meta-analysis","volume":"25","author":"Ans","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"10.1016\/j.clml.2025.04.016_bib0090","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/cncr.33967","article-title":"Extramedullary disease relapse and progression after blinatumomab therapy for treatment of acute lymphoblastic leukemia","volume":"128","author":"Aldoss","year":"2022","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.clml.2025.04.016_bib0091","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1182\/blood-2010-01-264077","article-title":"The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission","volume":"116","author":"Marks","year":"2010","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2025.04.016_bib0092","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/leu.2013.253","article-title":"Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease","volume":"28","author":"Bachanova","year":"2014","journal-title":"Leukemia"},{"issue":"22","key":"10.1016\/j.clml.2025.04.016_bib0093","doi-asserted-by":"crossref","first-page":"4439","DOI":"10.1182\/blood-2010-02-266551","article-title":"Reduced-intensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation","volume":"116","author":"Mohty","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2025.04.016_bib0094","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jtct.2023.09.028","volume":"30","author":"Battipaglia","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"10.1016\/j.clml.2025.04.016_bib0095","doi-asserted-by":"crossref","first-page":"e276","DOI":"10.1016\/S2352-3026(22)00036-9","article-title":"In-vivo T-cell depleted reduced-intensity conditioned allogeneic haematopoietic stem-cell transplantation for patients with acute lymphoblastic leukaemia in first remission: results from the prospective, single-arm evaluation of the UKALL14 trial","volume":"9","author":"Marks","year":"2022","journal-title":"Lancet Haematol"},{"issue":"6","key":"10.1016\/j.clml.2025.04.016_bib0096","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1182\/bloodadvances.2023011514","article-title":"A multicenter study of posttransplantation low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia","volume":"8","author":"Metheny","year":"2024","journal-title":"Blood Adv"},{"issue":"12","key":"10.1016\/j.clml.2025.04.016_bib0097","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1182\/blood.2021013290","article-title":"Blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia","volume":"139","author":"Gaballa","year":"2022","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2025.04.016_bib0098","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/s41409-023-01948-y","article-title":"Effects of post-transplant maintenance therapy with decitabine prophylaxis on the relapse for acute lymphoblastic leukemia","volume":"58","author":"Fan","year":"2023","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.clml.2025.04.016_bib0099","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1182\/bloodadvances.2021004916","article-title":"Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia","volume":"6","author":"Wieduwilt","year":"2022","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.clml.2025.04.016_bib0100","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41375-019-0544-3","article-title":"Haploidentical vs. unrelated allogeneic stem cell transplantation for acute lymphoblastic leukemia in first complete remission: on behalf of the ALWP of the EBMT","volume":"34","author":"Shem-Tov","year":"2020","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.clml.2025.04.016_bib0101","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1182\/bloodadvances.2020001499","article-title":"Comparing transplant outcomes in ALL patients after haploidentical with PTCy or matched unrelated donor transplantation","volume":"4","author":"Al Malki","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.clml.2025.04.016_bib0102","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13045-021-01094-2","article-title":"Post-transplant cyclophosphamide containing regimens after matched sibling, matched unrelated and haploidentical donor transplants in patients with acute lymphoblastic leukemia in first complete remission, a comparative study of the ALWP of the EBMT","volume":"14","author":"Sanz","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10.1016\/j.clml.2025.04.016_bib0103","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13045-020-00860-y","article-title":"Haploidentical donor is preferred over matched sibling donor for pre-transplantation MRD positive ALL: a phase 3 genetically randomized study","volume":"13","author":"Chang","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"23","key":"10.1016\/j.clml.2025.04.016_bib0104","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1002\/cncr.35004","volume":"129","author":"Giebel","year":"2023","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.clml.2025.04.016_bib0105","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1056\/NEJMsa1311707","article-title":"HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry","volume":"371","author":"Gragert","year":"2014","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.clml.2025.04.016_bib0106","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1182\/bloodadvances.2022009240","article-title":"Haploidentical vs matched unrelated donors for patients with ALL: donor age matters more than donor type","volume":"7","author":"Mehta","year":"2023","journal-title":"Blood Adv"},{"issue":"10","key":"10.1016\/j.clml.2025.04.016_bib0107","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.jtct.2023.07.015","article-title":"Younger matched unrelated donors confer decreased relapse risk compared to older sibling donors in older patients with B cell acute lymphoblastic leukemia undergoing allogeneic hematopoietic cell transplantation","volume":"29","author":"Abid","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"5","key":"10.1016\/j.clml.2025.04.016_bib0108","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.clml.2025.04.016_bib0109","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1200\/JCO.19.01892","article-title":"Optimizing chimeric antigen receptor T-cell therapy for adults with acute lymphoblastic leukemia","volume":"38","author":"Frey","year":"2020","journal-title":"J Clin Oncol"},{"issue":"30","key":"10.1016\/j.clml.2025.04.016_bib0110","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1200\/JCO.21.00917","article-title":"Durable responses and low toxicity after fast off-rate CD19 chimeric antigen receptor-T therapy in adults with relapsed or refractory B-cell acute lymphoblastic leukemia","volume":"39","author":"Roddie","year":"2021","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clml.2025.04.016_bib0111","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s13045-020-00953-8","article-title":"Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia","volume":"13","author":"Gu","year":"2020","journal-title":"J Hematol Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025001478?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025001478?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T05:07:19Z","timestamp":1758604039000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025001478"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":111,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S2152265025001478"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.04.016","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SOHO State of the Art Updates and Next Questions | Transplant in Adult Acute Lymphoblastic Leukemia","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.04.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}